Comparison of Foscarnet Versus Vidarabine in the Treatment of Herpes Infection in Patients With AIDS Who Have Not Had Success With Acyclovir - Related Studies

Comparison of Foscarnet Versus Vidarabine in the Treatment of Herpes Infection in Patients With AIDS Who Have Not Had Success With Acyclovir

This study has been completed.

Study NCT00000985. Last updated on August 25, 2008. Information provided by National Institute of Allergy and Infectious Diseases (NIAID)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Herpes Simplex
		HIV Infections

2	Additional conditions recognized in this trial
		Acquired Immunodeficiency Syndrome
		Communicable Diseases
		Immunologic Deficiency Syndromes
		Infection

3	More general conditions related to this trial
		DNA Virus Infections
		Herpesviridae Infections
		Immune System Diseases
		Lentivirus Infections
		Retroviridae Infections
		RNA Virus Infections
		Sexually Transmitted Diseases
		Sexually Transmitted Diseases, Viral
		Skin Diseases
		Skin Diseases, Infectious
		Skin Diseases, Viral
		Slow Virus Diseases
		Virus Diseases

4	Interventions listed in this trial
		Vidarabine
		Acyclovir
		Foscarnet sodium

5	Additional drug interventions recognized in this trial
		Foscarnet
		Phosphonoacetic Acid

6	More general drug interventions related to this trial
		Anti-Infective Agents
		Anti-Retroviral Agents
		Antimetabolites
		Antiviral Agents
		Enzyme Inhibitors
		Molecular Mechanisms of Pharmacological Action
		Nucleic Acid Synthesis Inhibitors
		Pharmacologic Actions
		Reverse Transcriptase Inhibitors
		Therapeutic Uses

7	Sponsors listed in this trial
		National Institute of Allergy and Infectious Diseases (NIAID)